Anavex Life Sciences Corp. (0HFR.L)
USD 8.21
(3.62%)
USD 8.21
(3.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 154.38 Million USD | 1.1% |
| 2022 | 152.7 Million USD | -5.51% |
| 2021 | 161.61 Million USD | 367.88% |
| 2020 | 34.54 Million USD | 36.37% |
| 2019 | 25.32 Million USD | 3.91% |
| 2018 | 24.37 Million USD | -12.44% |
| 2017 | 27.83 Million USD | 193.08% |
| 2016 | 9.49 Million USD | -38.6% |
| 2015 | 15.46 Million USD | 110.37% |
| 2014 | 7.35 Million USD | 1768.98% |
| 2013 | 393.44 Thousand USD | 2891.33% |
| 2012 | 13.15 Thousand USD | -93.52% |
| 2011 | 203.03 Thousand USD | -38.44% |
| 2010 | 329.84 Thousand USD | -19.28% |
| 2009 | 408.64 Thousand USD | 5560.66% |
| 2008 | 7219.00 USD | 28776.0% |
| 2007 | 25.00 USD | -99.8% |
| 2006 | 12.49 Thousand USD | 1178.92% |
| 2005 | 977.00 USD | -96.52% |
| 2004 | 28.11 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 141.62 Million USD | -2.22% |
| 2024 Q1 | 148.07 Million USD | -4.09% |
| 2024 Q2 | 144.75 Million USD | -2.24% |
| 2023 Q3 | 157.8 Million USD | -0.86% |
| 2023 Q4 | 154.38 Million USD | -2.17% |
| 2023 FY | 154.38 Million USD | 1.1% |
| 2023 Q1 | 148.37 Million USD | -2.84% |
| 2023 Q2 | 159.18 Million USD | 7.29% |
| 2022 Q3 | 160.22 Million USD | -0.03% |
| 2022 FY | 152.7 Million USD | -5.51% |
| 2022 Q4 | 152.7 Million USD | -4.69% |
| 2022 Q1 | 156.89 Million USD | -2.92% |
| 2022 Q2 | 160.27 Million USD | 2.15% |
| 2021 Q1 | 54.33 Million USD | 57.3% |
| 2021 FY | 161.61 Million USD | 367.88% |
| 2021 Q2 | 83.57 Million USD | 53.82% |
| 2021 Q3 | 166.41 Million USD | 99.13% |
| 2021 Q4 | 161.61 Million USD | -2.89% |
| 2020 Q1 | 31.42 Million USD | 24.06% |
| 2020 FY | 34.54 Million USD | 36.37% |
| 2020 Q2 | 31.02 Million USD | -1.28% |
| 2020 Q3 | 31.63 Million USD | 1.97% |
| 2020 Q4 | 34.54 Million USD | 9.21% |
| 2019 Q2 | 20.54 Million USD | -7.0% |
| 2019 Q1 | 22.09 Million USD | -9.36% |
| 2019 Q4 | 25.32 Million USD | 15.3% |
| 2019 FY | 25.32 Million USD | 3.91% |
| 2019 Q3 | 21.96 Million USD | 6.9% |
| 2018 Q4 | 24.37 Million USD | -9.03% |
| 2018 FY | 24.37 Million USD | -12.44% |
| 2018 Q3 | 26.79 Million USD | 3.47% |
| 2018 Q1 | 28.34 Million USD | 1.82% |
| 2018 Q2 | 25.89 Million USD | -8.64% |
| 2017 Q3 | 24.9 Million USD | 5.51% |
| 2017 Q4 | 27.83 Million USD | 11.77% |
| 2017 Q1 | 21.37 Million USD | 125.02% |
| 2017 FY | 27.83 Million USD | 193.08% |
| 2017 Q2 | 23.6 Million USD | 10.45% |
| 2016 FY | 9.49 Million USD | -38.6% |
| 2016 Q1 | 14.02 Million USD | -9.35% |
| 2016 Q2 | 12.11 Million USD | -13.61% |
| 2016 Q4 | 9.49 Million USD | -3.51% |
| 2016 Q3 | 9.84 Million USD | -18.75% |
| 2015 Q1 | 7.05 Million USD | -4.12% |
| 2015 Q3 | 8.04 Million USD | 26.37% |
| 2015 FY | 15.46 Million USD | 110.37% |
| 2015 Q2 | 6.36 Million USD | -9.73% |
| 2015 Q4 | 15.46 Million USD | 92.34% |
| 2014 Q1 | 150.88 Thousand USD | -61.65% |
| 2014 Q2 | 10.29 Million USD | 6721.34% |
| 2014 Q3 | 9.31 Million USD | -9.51% |
| 2014 Q4 | 7.35 Million USD | -21.05% |
| 2014 FY | 7.35 Million USD | 1768.98% |
| 2013 Q2 | 487.00 USD | -99.39% |
| 2013 Q3 | 3480.00 USD | 614.58% |
| 2013 FY | 393.44 Thousand USD | 2891.33% |
| 2013 Q1 | 79.9 Thousand USD | 507.47% |
| 2013 Q4 | 393.44 Thousand USD | 11206.01% |
| 2012 Q2 | 191.1 Thousand USD | 125.91% |
| 2012 Q1 | 84.59 Thousand USD | -58.34% |
| 2012 FY | 13.15 Thousand USD | -93.52% |
| 2012 Q4 | 13.15 Thousand USD | -40.58% |
| 2012 Q3 | 22.13 Thousand USD | -88.42% |
| 2011 FY | 203.03 Thousand USD | -38.44% |
| 2011 Q4 | 203.03 Thousand USD | -84.13% |
| 2011 Q1 | 489.28 Thousand USD | 48.34% |
| 2011 Q3 | 1.27 Million USD | 1873.09% |
| 2011 Q2 | 64.83 Thousand USD | -86.75% |
| 2010 FY | 329.84 Thousand USD | -19.28% |
| 2010 Q2 | 229.09 Thousand USD | 215.28% |
| 2010 Q3 | 1.57 Million USD | 585.96% |
| 2010 Q1 | 72.66 Thousand USD | -82.22% |
| 2010 Q4 | 329.84 Thousand USD | -79.01% |
| 2009 Q1 | 1386.00 USD | -80.8% |
| 2009 Q4 | 408.64 Thousand USD | -48.85% |
| 2009 Q3 | 798.95 Thousand USD | 906.1% |
| 2009 Q2 | 79.41 Thousand USD | 5629.51% |
| 2009 FY | 408.64 Thousand USD | 5560.66% |
| 2008 Q3 | 111.66 Thousand USD | 20.2% |
| 2008 Q1 | 130.58 Thousand USD | 522228.0% |
| 2008 Q4 | 7219.00 USD | -93.53% |
| 2008 FY | 7219.00 USD | 28776.0% |
| 2008 Q2 | 92.89 Thousand USD | -28.86% |
| 2007 Q4 | 25.00 USD | -78.81% |
| 2007 Q2 | 15.02 Thousand USD | 232.64% |
| 2007 Q1 | 4516.00 USD | -63.86% |
| 2007 Q3 | 118.00 USD | -99.21% |
| 2007 FY | 25.00 USD | -99.8% |
| 2006 Q3 | 19.88 Thousand USD | 15193.08% |
| 2006 Q2 | 130.00 USD | 0.0% |
| 2006 Q4 | 12.49 Thousand USD | -37.15% |
| 2006 FY | 12.49 Thousand USD | 1178.92% |
| 2006 Q1 | 130.00 USD | -86.69% |
| 2005 Q4 | 977.00 USD | 0.0% |
| 2005 FY | 977.00 USD | -96.52% |
| 2004 FY | 28.11 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 81.437% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 83.525% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 80.153% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 6.718% |
| bluebird bio, Inc. | 619.16 Million USD | 75.065% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -22.68% |
| Imunon, Inc. | 21.91 Million USD | -604.378% |
| Editas Medicine, Inc. | 499.15 Million USD | 69.07% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.421% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 95.399% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 87.121% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 95.252% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 89.043% |
| Verastem, Inc. | 149.71 Million USD | -3.118% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.809% |
| Waters Corporation | 4.62 Billion USD | 96.663% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.844% |
| Biogen Inc. | 26.84 Billion USD | 99.425% |
| Nektar Therapeutics | 398.03 Million USD | 61.213% |
| Perrigo Company plc | 10.8 Billion USD | 98.572% |
| Dynavax Technologies Corporation | 997.09 Million USD | 84.516% |
| Illumina, Inc. | 10.11 Billion USD | 98.473% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -446.066% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 80.216% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 30.615% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -135.022% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.743% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 6.614% |
| Evolus, Inc. | 188.99 Million USD | 18.313% |
| Adicet Bio, Inc. | 207.29 Million USD | 25.524% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 21.792% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.533% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 24.981% |
| FibroGen, Inc. | 423.52 Million USD | 63.548% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.566% |
| OPKO Health, Inc. | 2.01 Billion USD | 92.326% |
| Homology Medicines, Inc. | 47.05 Million USD | -228.083% |
| Geron Corporation | 394.07 Million USD | 60.823% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 95.969% |
| Exelixis, Inc. | 2.94 Billion USD | 94.753% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 58.103% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 88.133% |
| Zoetis Inc. | 14.28 Billion USD | 98.919% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 73.754% |
| Abeona Therapeutics Inc. | 64 Million USD | -141.221% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.321% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -175.941% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 94.837% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 95.271% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 75.16% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 91.093% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 85.286% |
| Insmed Incorporated | 1.32 Billion USD | 88.391% |
| TG Therapeutics, Inc. | 329.58 Million USD | 53.158% |
| Incyte Corporation | 6.78 Billion USD | 97.724% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 91.586% |